icon-folder.gif   Conference Reports for NATAP  
 
  16th International Workshop
on Clinical Pharmacology of HIV
and Hepatitis Therapy
May 26-28, 2015
Washington, DC
Back grey_arrow_rt.gif
 
 
 
Assessment of Drug-Drug Interactions Between Daclatasvir
and Darunavir/Ritonavir or Lopinavir/Ritonavir

 
 
  Reported by Jules Levin
16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. Washington DC, May 26-28, 2015
 
Gandhi Y, Adamczyk R, Wang R, Stonier M, Kandoussi H, Hesney M, Liu Z, Ackerman P, Garimella T, Eley T
Bristol-Myers Squibb Research & Development, Princeton, NJ

Pharm1.gif

EASL: Daclatasvir Plus Sofosbuvir for Treatment of HCV Genotypes 1-4 in HIV-HCV Coinfection: The ALLY-2 Study - (04/28/15)
 
Daclatasvir: Overview of Drug-Drug Interactions With Antiretroviral Agents and Other Common Concomitant Drugs........[Eley T et al. HIV DART 2014] ........http://www.natap.org/2014/HCV/121714_01.htm
 

Pharm2.gif

Pharm3.gif

Pharm4.gif

Pharm5.gif

Pharm6.gif

Pharm7.gif

Pharm8.gif

Pharm9.gif

Pharm10.gif